Valneva SE (VALN) Equity Average (2022 - 2023)
Valneva SE's (VALN) quarterly Equity Average came in at $222.0 million in Q1 2023, up 22.77% year-on-year from $180.9 million in Q1 2022, and up 13.69% quarter-over-quarter from $195.3 million in Q4 2022.
Valneva SE (VALN) Equity Average (2022 - 2023) Analysis & Trends
Valneva SE has disclosed Equity Average across 2 years of filings, most recently posting $222.0 million for Q1 2023.
- Equity Average for Q1 2023 came in at $222.0 million, up 22.77% year-over-year; the trailing twelve-month figure through Mar 2023 was $222.0 million (up 22.77% YoY), and the FY2022 annual result was $213.1 million, down 11.52% from the prior year.
- Equity Average came in at $222.0 million for Q1 2023 at Valneva SE, up from $195.3 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $222.0 million in Q1 2023 to a low of $132.9 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 21.35 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 516.41 Mn |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 222.02 Mn |
| Dec 31, 2022 | 195.30 Mn |
| Sep 30, 2022 | 132.93 Mn |
| Jun 30, 2022 | 133.04 Mn |
| Mar 31, 2022 | 180.85 Mn |